FindTrial
Sign In

Socio-economic impact of tocilizumab (TCZ), other bDMARD and tsDMARD treatment on Japanese Rheumatoid Arthritis patients

Socio-economic impact of tocilizumab (TCZ), other bDMARD and tsDMARD treatment on Japanese Rheumatoid Arthritis patients using CorEvitas' RA Japan registry - Socio-economic impact of tocilizumab (TCZ), other bDMARD and tsDMARD treatment on Japanese Rheumatoid Arthritis patients using CorEvitas' RA Japan registry

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000044713
Enrollment
500
Registered
2021-07-01
Start date
2021-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Sponsors

CHUGAI PHARMACEUTICAL CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Key inclusion criteria of CorEvitas' RA Japan registry is following: 1) The subject must be diagnosed with rheumatoid arthritis according to the 1987 ACR or the ACR/EULAR 2010 Rheumatoid Arthritis Classification Criteria 2) The subject must be at least 18 years of age or older 3) The subject must be able and willing to provide written consent 4) The subject must be prescribed or switching to an eligible medication or the first time ever at the Enrollment Visit. History of or concomitant treatment with other eligible medications does not exclude a subject from enrollment. This analysis will include only biologic-naive and JAK-naive initiators of the following drugs: TCZ [tocilizumab] TNFi [infliximab, etanercept, adalimumab, certolizumab pegol, golimumab] CTLA4 [abatacept] JAKi [tofacitinib, baricitinib]

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

MeasureTime frame
Change of Socio-economic impact of TCZ from 12month to baseline—

Countries

Japan

Contacts

Public ContactNobuo Nishijima

CHUGAI PHARMACEUTICAL CO., LTD. Medical Affairs Div.

cma-clinicaltrial@chugai-pharm.co.jp03-3273-0866

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026